Erratum: CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett, Emmanuelle di Tomaso(Bayer (United States)), Dan G. Duda(Harvard University), Kenneth S. Cohen(University of Chicago), Yves Boucher(Harvard University), Gregory Y. Lauwers(Moffitt Cancer Center), Helen X Chen(National Cancer Institute), Paul C. Shellito(Harvard University), Alan J. Fischman(Shriners Hospitals for Children), Sanjeeva P. Kalva(Massachusetts General Hospital), David P. Ryan(East Carolina University), Sergey V. Kozin(Sechenov University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), David T. Scadden(Harvard University), Alan C. Hartford(Dartmouth College), Daniel C. Chung(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Ricky T. Tong(Harvard University), Mari Mino(Harvard University), Lance L. Munn(Massachusetts General Hospital), Dushyant V. Sahani(University of Washington)
Cited by 21
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k